ClinicalTrials.gg
RecruitingNCT06389019Updated Nov 9, 2026

Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer

An observational study in Bladder Cancer, sponsored by Mingzhao Xiao. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Mingzhao Xiao · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 9, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
4th of 53
2,000 · median 266
Started
2024
with 23 others
Observational
53 of 194
28 open now
Primary completion
2027-12
later than 74 of 118 live
Registered
118th of 194
by date

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 4th largest by planned enrollment of the 53 observational ones that give a count, is one of 24 that started in 2024, is one of 53 observational ones, reaches primary completion later than 74 of the 118 other live ones, and was the 118th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA.This observational study evaluates a deep learning system that combines CT images and digitized pathology slides to predict outcomes in patients with bladder cancer. It includes a retrospective cohort and a prospective cohort of newly enrolled patients. The prospective cohort will assess the system in patients enrolled during (2024-2026), with follow-up for survival and recurrence.

Read the detailed description

Study structure The study includes an initial retrospective phase and a subsequent prospective observational phase involving newly enrolled patients. The two phases are analyzed separately according to the specified analysis plan.

Retrospective phase The retrospective phase included patients from [2012-2024] and was used for model construction. Results from this phase were reported in npj series.

Prospective phase Enrollment of newly recruited patients began on [2024]. The prospective phase follows protocol, with ethics approval from the first affliated hospital of chongqing medical, university. Recruitment is consecutive, as specified in the protocol.

Model evaluation The prospective cohort is used for validation. The model version, preprocessing procedures and prediction thresholds used in this phase. Any model updating using this cohort is documented separately.

Registry update This update distinguishes the retrospective phase from the subsequently enrolled cohort. The prospective phase enrollment dates and the dates of protocol development and ethics approval are reported separately.

03

Conditions studied

  • Bladder Cancer

Keywords

  • deep learning
  • Radiomics
  • Histopathological tissue slides
  • Tomography
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We included patients who had surgery only or who had neoadjuvant chemotherapy before surgery. We excluded patients with a postoperative diagnosis of non-urothelial carcinoma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with bladder cancer who had surgery like radical cystectomy or transurethral resection of bladder tumour (TURBT)
  • contrast-CT scan less than two weeks before surgery
  • complete CT image data and clinical data
  • complete whole slide image data

Exclusion criteria

Exclusion Criteria:

  • patients with a postoperative diagnosis of non-urothelial carcinoma
  • poor quality of CT images
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective cohort

    Patients with bladder cancer included in the retrospective phase of the study, using clinical records, CT images, and whole-slide images obtained during \[2012-2024\]. This cohort was used for model development and/or validation and was reported in our npj publications.

    Other: Deep learning system for prognostication prediction in bladder cancer

  • Prospective cohort of newly enrolled patients

    Newly enrolled patients with bladder cancer recruited at four centers between 2024 and2026. Eligibility is assessed at enrollment, and participants are followed according to protocol version and date for the study outcomes. This cohort is distinct from the previously reported retrospective cohort.

    Other: Deep learning system for prognostication prediction in bladder cancer

Interventions

  • OtherDeep learning system for prognostication prediction in bladder cancer

    develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.

06

What researchers measure

Primary outcomes

  1. Overall survival

    the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off.

    Time frame: up to 10 years

Secondary outcomes

  1. Recurrence free survival

    the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored

    Time frame: up to 10 years

  2. progression-free survival

    The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works. Also called PFS.

    Time frame: up to 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The datasets analyzed during the current study are not publicly available due to the privacy of patients but are available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 168 non-industry observational studies under Urinary Bladder Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30. This study's planned 47 months is below that.

Counting every sponsor, half of 203 studies reached it within 58 months; a quarter within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2025 → Dec 2027 and completion Oct 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Apr 29, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Dec 1, 2027was Jun 2025
CompletionEst.
Dec 1, 2027was Oct 2025
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
Show 1 removed
  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
Nov 9, 2026
Primary completion
Jun 1, 2025→Dec 1, 2027
Nov 9, 2026
Study completion
Oct 1, 2025→Dec 1, 2027
Nov 9, 2026
Enrollment
1000→2000
Nov 9, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • Removedincomplete clinical and follow-up data
Nov 9, 2026
Interventions
Arms added: Retrospective cohort·Prospective cohort of newly enrolled patients; arms removed: BLCA
Nov 9, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • Addedprogression-free survivalTime frame: up to 10 years
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added, 1 site removed
    Show site
    • Department of Urology, The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
    Show 1 removed
    • Department of Urology, The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
    Primary completion Jun 1, 2025→Dec 1, 2027
    Study completion Oct 1, 2025→Dec 1, 2027
    Enrollment 1000→2000
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • Removedincomplete clinical and follow-up data
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedprogression-free survivalTime frame: up to 10 years
    Interventions Arms added: Retrospective cohort·Prospective cohort of newly enrolled patients; arms removed: BLCA
    + 4 other changes: verification date, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06389019
Lead sponsor
Mingzhao Xiao
Responsible party
Mingzhao Xiao (Professor, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Apr 29, 2024
Start date
Jan 1, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

QuanHao He
Contact
2020120460@stu.cqmu.edu.cn
800-555-5555
Mingzhao Xiao, PHD
Contact
2023140134@stu.cqmu.edu.cn
800-555-5555

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion